AC Immune SA
ACIU
$2.91
-$0.05-1.53%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.01% | -2.06% | -3.61% | -3.61% | -235.75% |
| Total Depreciation and Amortization | 36.11% | 24.62% | 7.06% | 7.06% | -3.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 195.68% | -70.38% | 746.45% | 746.45% | -144.58% |
| Change in Net Operating Assets | -118.67% | -96.83% | -112.33% | -112.33% | 254.20% |
| Cash from Operations | -405.80% | -123.41% | -1,887.09% | -1,887.09% | 136.95% |
| Capital Expenditure | -30.63% | -501.33% | -41.40% | -41.40% | 45.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 573.99% | 135.08% | 114.14% | 114.14% | -116.07% |
| Cash from Investing | 559.78% | 134.53% | 112.50% | 112.50% | -116.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -52.05% | -47.40% | -51.50% | -51.50% | -23.02% |
| Issuance of Common Stock | -- | -97.78% | -- | -- | -- |
| Repurchase of Common Stock | 96.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 120.83% | 99.04% | 99.04% | -- |
| Cash from Financing | -45.65% | -336.44% | 63.53% | 63.53% | -100.48% |
| Foreign Exchange rate Adjustments | -110.16% | 3.82% | -115.03% | -115.03% | 226.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -126.95% | 216.01% | 26.15% | 26.15% | -91.65% |